Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis
- 1 March 2005
- journal article
- other
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 90 (1) , 15-23
- https://doi.org/10.1007/s10549-004-1668-2
Abstract
Summary Impaired histone acetylation was recognized to be involved in carcinogenesis. Furthermore, histone deacetylase (HDAC) inhibitors induce differentiation of breast cancer cells and inhibit tumour growth. These results prompted us to study HDAC-1 and -3 expression in breast tumours to establish their potential therapeutic and prognostic significance. HDAC-1 und HDAC-3 protein expression was analyzed immunohistochemically on a tissue microarray (TMA) containing 600 core biopsies from 200 patients. HDAC-1 and -3 expression was correlated to steroid hormone receptor-, Her2/neu- and proliferation status of tumours as well as to overall and disease free survival. Moderate or strong nuclear immunoreactivity for HDAC-1 was observed in 39.8% and for HDAC-3 in 43.9% of breast carcinomas. HDAC-1 and -3 expression correlated significantly with oestrogen and progesterone receptor expression (both p< 0.001). HDAC-1 expression predicted significantly better disease free survival (DFS: p=0.044), in particular, in patients with small tumours of all differentiation types (DFS: p=0.016). Multivariate analysis demonstrated that HDAC-1 is an independent prognostic marker. Our data suggest that evaluation of HDAC-1 protein expression enables a more precise assessment of the prognosis of breast cancer patients. Thus, HDAC-1 expression analysis might be clinically useful to facilitate an individual, risk-directed, adjuvant systemic therapy in breast cancer patients.Keywords
This publication has 21 references indexed in Scilit:
- The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifenOncogene, 2003
- A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidineBreast Cancer Research and Treatment, 2003
- Cancer epigeneticsOncogene, 2003
- Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysisZeitschrift für Krebsforschung und Klinische Onkologie, 2003
- The Tumor Suppressor p53 and Histone Deacetylase 1 Are Antagonistic Regulators of the Cyclin-Dependent Kinase Inhibitor p21/WAF1/CIP1 GeneMolecular and Cellular Biology, 2003
- Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repressionThe EMBO Journal, 2002
- The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3Molecular and Cellular Biology, 2001
- Rb-mediated chromatin structure regulation and transcriptional repressionOncogene, 2001
- Histone deacetylases, transcriptional control, and cancerJournal of Cellular Physiology, 2000
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998